Gilead
 
2010 News Releases
Receive E-mail AlertsE-mail Alerts
Keyword Search
2010 | 2009 | 2008 | 2007 | 2006 | 2005
| Archived
DateTitle 
09/01/10Gilead Provides Update on $5 Billion Stock Repurchase ProgramPrinter Friendly Version
08/19/10Gilead Sciences Announces Notification of ANDA Filing for Hepsera(R)Printer Friendly Version
07/30/10Gilead Closes Sale of $2.2 Billion of Convertible Senior NotesPrinter Friendly Version
07/27/10Gilead Prices $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common StockPrinter Friendly Version
07/26/10Gilead to Offer $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common StockPrinter Friendly Version
07/20/10Gilead Sciences Announces Second Quarter 2010 Financial ResultsPrinter Friendly Version
07/14/10Gilead Sciences Files Patent Infringement Lawsuit Against Lupin LimitedPrinter Friendly Version
07/13/10Gilead Sciences to Release Second Quarter 2010 Financial Results on Tuesday, July 20, 2010Printer Friendly Version
06/25/10Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 MillionPrinter Friendly Version
06/18/10Gilead's Head-to-Head Study of Cayston(R) Versus Tobramycin Inhalation Solution in Cystic Fibrosis Patients Achieves Co-Primary Efficacy Endpoint of Non-InferiorityPrinter Friendly Version
06/10/10Gilead Sciences Announces Notification of ANDA Filing for Ranexa(R)Printer Friendly Version
06/09/10Gilead Sciences to Present at Two Upcoming Investor ConferencesPrinter Friendly Version
06/08/10John G. McHutchison, MD, to Join Gilead Sciences as Senior Vice President, Liver Disease TherapeuticsPrinter Friendly Version
06/04/10Gilead Sciences and ADAP Crisis Task Force Announce New Initiatives to Support AIDS Drug Assistance Programs (ADAPs)Printer Friendly Version
06/02/10Gilead Sciences to Present at the Jefferies 2010 Global Life Sciences Conference on Wednesday, June 9Printer Friendly Version
05/27/10Gilead Sciences to Present at the Sanford C. Bernstein 26th Annual Strategic Decisions Conference on Thursday, June 3Printer Friendly Version
05/19/10Gilead Sciences to Present at the 2010 Citi Investment Research Global Health Care Conference on Wednesday, May 26Printer Friendly Version
05/11/10Gilead Announces $5 Billion Share Repurchase ProgramPrinter Friendly Version
05/06/10Gilead Sciences to Present at the Banc of America Merrill Lynch 2010 Healthcare Conference on Thursday, May 13Printer Friendly Version
04/27/10Gilead Finalizes Selection of Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals' TMC278Printer Friendly Version
04/20/10Gilead Sciences Announces Record First Quarter 2010 Financial ResultsPrinter Friendly Version
04/20/10Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals' TMC278Printer Friendly Version
04/19/10Gilead Terminates Phase II Clinical Trial of GS 9450 in Patients With Chronic Hepatitis CPrinter Friendly Version
04/13/10Gilead Sciences to Release First Quarter 2010 Financial Results on Tuesday, April 20, 2010Printer Friendly Version
04/12/10Gilead Initiates Phase III Clinical Program Evaluating Single-Tablet, Once-Daily "Quad" Regimen for HIVPrinter Friendly Version
03/17/10Gilead Sciences to Present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24Printer Friendly Version
03/04/10Gilead Sciences to Present at the Cowen and Company 30th Annual Health Care Conference on Thursday, March 11Printer Friendly Version
02/22/10U.S. Food and Drug Administration Approves Cayston(R) (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas AeruginosaPrinter Friendly Version
02/17/10Gilead's Single-Tablet "Quad" Regimen for HIV Achieves a High Rate of Virologic Suppression in Phase II StudyPrinter Friendly Version
02/02/10Gilead Sciences to Present at the 12th Annual BIO CEO Investor Conference on Tuesday, February 9Printer Friendly Version
01/29/10Gilead Announces Share Repurchase ProgramPrinter Friendly Version
01/28/10Per Wold-Olsen Joins Gilead Sciences' Board of DirectorsPrinter Friendly Version
01/27/10Gilead Sciences Announces Notification of ANDA Filing for Viread®Printer Friendly Version
01/26/10Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial ResultsPrinter Friendly Version
01/19/10Gilead Sciences to Release Fourth Quarter and Year End 2009 Financial Results on Tuesday, January 26, 2010Printer Friendly Version
01/06/10Phase II Clinical Trial of Gilead's Investigational Integrase-Based, Once-Daily, Fixed-Dose "Quad" Regimen Meets 24-Week Primary ObjectivePrinter Friendly Version
01/04/10Gilead Sciences to Present at Two Upcoming Investor ConferencesPrinter Friendly Version

The information in these news pages should not be deemed accurate or current except as of the date of the particular press release or posting. Gilead has no intention of updating and specifically disclaims any duty to update the information in the press releases. The press releases may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties.